1. at receptor antagonists D Long-acting Phenoxybenzamine酚苄明 Longer action duration used for peripheral vasculardiseases anti-shock pheochromocytoma improving urinary flow in patients with benign prostatic hypertrophy
Long-acting Longer action duration used for peripheral vasculardiseases anti-shock pheochromocytoma improving urinary flow in patients with benign prostatic hypertrophy Phenoxybenzamine 酚苄明 1. receptor antagonists
1. at receptor antagonists u 1-2 O, receptor antagonists 口 prazosin(哌唑嗪), for hypertension treatment tamsulosin(坦洛新), for benign prostatic hypertrophy o 1-3 a, receptor antagonists yohimbine(育亨宾)
1-2 1 receptor antagonists prazosin（哌唑嗪）, for hypertension treatment tamsulosin（坦洛新）, for benign prostatic hypertrophy 1-3 2 receptor antagonists yohimbine（育亨宾） 1. receptor antagonists
2. B receptor antagonists 日21ADME u First-pass elimination u lower bioavailability: propranolol u Hepatic metabolism and renal excretion, hepatic and renal functions alter the effects of the drugs and result in large individual variation u Thus, dose individualization is necessary
2.1 ADME First-pass elimination, lower bioavailability: propranolol Hepatic metabolism and renal excretion, hepatic and renal functions alter the effects of the drugs and result in large individual variation Thus, dose individualization is necessary. 2. receptor antagonists